# Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer

> **NCT02125617** · — · TERMINATED · sponsor: **Kristoffer Rohrberg** · enrollment: 3 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Abiraterone
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT02125617
- **Lead sponsor:** Kristoffer Rohrberg
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2016-07-15
- **Final completion:** 2017-02-14
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor recruition
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125617, "Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02125617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*